

# Gennari Luigi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/877199/publications.pdf>

Version: 2024-02-01

168  
papers

6,529  
citations

50244

46  
h-index

82499

72  
g-index

171  
all docs

171  
docs citations

171  
times ranked

6163  
citing authors

#	ARTICLE	IF	CITATIONS
1	Longitudinal Association between Sex Hormone Levels, Bone Loss, and Bone Turnover in Elderly Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5327-5333.	1.8	223
2	Circulating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1737-1744.	1.8	222
3	Estrogen Receptor Gene Polymorphisms and the Genetics of Osteoporosis: A HuGE Review. <i>American Journal of Epidemiology</i> , 2005, 161, 307-320.	1.6	201
4	Association of Polymorphisms of the Estrogen Receptor $\hat{\pm}$ Gene With Bone Mineral Density and Fracture Risk in Women: A Meta-Analysis. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 2048-2060.	3.1	182
5	Vitamin D and Estrogen Receptor Allelic Variants in Italian Postmenopausal Women: Evidence of Multiple Gene Contribution to Bone Mineral Density. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 939-944.	1.8	173
6	Evidence of a linkage disequilibrium between polymorphisms in the human estrogen receptor alpha gene and their relationship to bone mass variation in postmenopausal Italian women. <i>Human Molecular Genetics</i> , 2000, 9, 2043-2050.	1.4	164
7	Aromatase Activity and Bone Homeostasis in Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 5898-5907.	1.8	164
8	Genome-wide association identifies three new susceptibility loci for Paget's disease of bone. <i>Nature Genetics</i> , 2011, 43, 685-689.	9.4	158
9	A Polymorphic CYP19 TTTA Repeat Influences Aromatase Activity and Estrogen Levels in Elderly Men: Effects on Bone Metabolism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2803-2810.	1.8	151
10	Association of the Estrogen Receptor $\hat{\pm}$ Gene Polymorphisms with Sporadic Alzheimer's Disease. <i>Biochemical and Biophysical Research Communications</i> , 1999, 265, 335-338.	1.0	122
11	Vitamin D Status and SARS-CoV-2 Infection and COVID-19 Clinical Outcomes. <i>Frontiers in Public Health</i> , 2021, 9, 736665.	1.3	108
12	Endocrine Actions of Osteocalcin. <i>International Journal of Endocrinology</i> , 2013, 2013, 1-10.	0.6	105
13	Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 579-604.	3.1	102
14	Selective Estrogen Receptor Modulators for Postmenopausal Osteoporosis. <i>Drugs and Aging</i> , 2007, 24, 361-379.	1.3	95
15	FokI Polymorphism at Translation Initiation Site of the Vitamin D Receptor Gene Predicts Bone Mineral Density and Vertebral Fractures in Postmenopausal Italian Women. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 1379-1386.	3.1	94
16	Polymorphism of the Aromatase Gene in Postmenopausal Italian Women: Distribution and Correlation with Bone Mass and Fracture Risk <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2263-2269.	1.8	93
17	Mechanisms of impaired bone strength in type 1 and 2 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 683-690.	1.1	92
18	Vitamin D Receptor Genotypes and Intestinal Calcium Absorption in Postmenopausal Women. <i>Calcified Tissue International</i> , 1997, 61, 460-463.	1.5	90

#	ARTICLE	IF	CITATIONS
19	Polymorphisms of the Calcitonin Receptor Gene Are Associated with Bone Mineral Density in Postmenopausal Italian Women. <i>Biochemical and Biophysical Research Communications</i> , 1998, 248, 190-195.	1.0	90
20	FSHR gene polymorphisms influence bone mineral density and bone turnover in postmenopausal women. <i>European Journal of Endocrinology</i> , 2010, 163, 165-172.	1.9	87
21	Osteoporosis in Men. <i>Endocrinology and Metabolism Clinics of North America</i> , 2007, 36, 399-419.	1.2	86
22	Genetics of osteoporosis: role of steroid hormone receptor gene polymorphisms. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2002, 81, 1-24.	1.2	83
23	Quantitative ultrasound and dual-energy X-ray absorptiometry in the prediction of fragility fracture in men. <i>Osteoporosis International</i> , 2005, 16, 963-968.	1.3	83
24	Alendronate Treatment in Men With Primary Osteoporosis: A Three-Year Longitudinal Study. <i>Calcified Tissue International</i> , 2003, 73, 133-139.	1.5	82
25	Vitamin D and COVID-19 severity and related mortality: a prospective study in Italy. <i>BMC Infectious Diseases</i> , 2021, 21, 566.	1.3	81
26	MicroRNAs in bone diseases. <i>Osteoporosis International</i> , 2017, 28, 1191-1213.	1.3	75
27	The Effects of Recombinant TSH on Bone Turnover Markers and Serum Osteoprotegerin and RANKL Levels. <i>Thyroid</i> , 2008, 18, 455-460.	2.4	74
28	Prevalence of Paget's Disease of Bone in Italy. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 1845-1850.	3.1	72
29	Comparison of Different Intravenous Bisphosphonate Regimens for Paget's Disease of Bone. <i>Journal of Bone and Mineral Research</i> , 2007, 22, 1510-1517.	3.1	71
30	Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone. <i>Bone</i> , 2007, 40, 457-463.	1.4	69
31	Membrane binding sites and non-genomic effects of estrogen in cultured human preosteoclastic cells. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1996, 59, 233-240.	1.2	67
32	The combined use of ultrasound and densitometry in the prediction of vertebral fracture.. <i>British Journal of Radiology</i> , 1997, 70, 691-696.	1.0	65
33	<i>Helicobacter pylori</i> infection and infertility. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 663-669.	0.8	64
34	Characteristics and Familial Aggregation of Paget's Disease of Bone in Italy. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 1356-1364.	3.1	64
35	SQSTM1 gene analysis and gene-environment interaction in Paget's disease of bone. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 1375-1384.	3.1	64
36	Treatment needs and current options for postmenopausal osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1141-1152.	0.9	63

#	ARTICLE	IF	CITATIONS
37	ZNF687 Mutations in Severe Paget Disease of Bone Associated with Giant Cell Tumor. American Journal of Human Genetics, 2016, 98, 275-286.	2.6	61
38	Paget's Disease of Bone in Italy. Journal of Bone and Mineral Research, 2006, 21, P14-P21.	3.1	60
39	Paget's Disease of Bone. Calcified Tissue International, 2019, 104, 483-500.	1.5	59
40	Evidence for Increased Clinical Severity of Familial and Sporadic Paget's Disease of Bone in Campania, Southern Italy. Journal of Bone and Mineral Research, 2006, 21, 1828-1835.	3.1	58
41	Vitamin D Status and Bone Turnover in Women with Acute Hip Fracture. Clinical Orthopaedics and Related Research, 2004, 422, 208-213.	0.7	56
42	Pathophysiology and Management of Type 2 Diabetes Mellitus Bone Fragility. Journal of Diabetes Research, 2020, 2020, 1-18.	1.0	55
43	Heel Ultrasonography in Monitoring Alendronate Therapy: A Four-Year Longitudinal Study. Osteoporosis International, 2002, 13, 415-421.	1.3	52
44	Allelic Variants of Human Calcitonin Receptor: Distribution and Association with Bone Mass in Postmenopausal Italian Women. Biochemical and Biophysical Research Communications, 1998, 245, 622-626.	1.0	51
45	Effect of electromagnetic fields on bone mineral density and biochemical markers of bone turnover in osteoporosis: a single-blind, randomized pilot study. Current Therapeutic Research, 2001, 62, 187-193.	0.5	51
46	Common susceptibility alleles and <i>SQSTM1</i> mutations predict disease extent and severity in a multinational study of patients with Paget's disease. Journal of Bone and Mineral Research, 2013, 28, 2338-2346.	3.1	50
47	Prevalence of Helicobacter pylori Infection in Male Patients with Osteoporosis and Controls. Digestive Diseases and Sciences, 2005, 50, 847-852.	1.1	48
48	Lasofixifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis. Expert Opinion on Investigational Drugs, 2006, 15, 1091-1103.	1.9	47
49	Dual X-ray Absorptiometry and Bone Ultrasonography in Patients with Rett Syndrome. Calcified Tissue International, 2001, 69, 259-262.	1.5	45
50	Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofixifene. Clinical Interventions in Aging, 2010, 5, 19.	1.3	45
51	Clinical Guidelines on Paget's Disease of Bone. Journal of Bone and Mineral Research, 2019, 34, 2327-2329.	3.1	43
52	Estrogen and Fracture Risk in Men. Journal of Bone and Mineral Research, 2008, 23, 1548-1551.	3.1	42
53	The relationship between plasma homocysteine levels and bone mineral density in post-menopausal women. European Journal of Internal Medicine, 2010, 21, 301-305.	1.0	42
54	Age-Related Decline of Bone Mass and Intestinal Calcium Absorption in Normal Males. Calcified Tissue International, 1998, 63, 197-201.	1.5	40

#	ARTICLE	IF	CITATIONS
55	DIAGNOSIS OF ENDOCRINE DISEASE: Evaluation of bone fragility in endocrine disorders. European Journal of Endocrinology, 2019, 180, R213-R232.	1.9	40
56	Quantitative Ultrasound and Bone Mineral Density in Patients with Primary Hyperparathyroidism Before and after Surgical Treatment. Osteoporosis International, 2000, 11, 255-260.	1.3	39
57	Bisphosphonates Target B Cells to Enhance Humoral Immune Responses. Cell Reports, 2013, 5, 323-330.	2.9	39
58	Clinical Characteristics and Evolution of Giant Cell Tumor Occurring in Paget's Disease of Bone. Journal of Bone and Mineral Research, 2015, 30, 257-263.	3.1	38
59	Genetics of Male Osteoporosis. Calcified Tissue International, 2001, 69, 200-204.	1.5	36
60	Beyond Glycemic Control in Diabetes Mellitus: Effects of Incretin-Based Therapies on Bone Metabolism. Frontiers in Endocrinology, 2013, 4, 73.	1.5	36
61	Genotype distribution of estrogen receptor- $\alpha$ gene polymorphisms in italian women with surgical uterine leiomyomas. Fertility and Sterility, 2001, 75, 567-570.	0.5	35
62	A nonsynonymous <i>TNFRSF11A</i> variation increases NF $\kappa$ B activity and the severity of Paget's disease. Journal of Bone and Mineral Research, 2012, 27, 443-452.	3.1	34
63	Raloxifene in breast cancer prevention. Expert Opinion on Drug Safety, 2008, 7, 259-270.	1.0	33
64	Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy. Expert Opinion on Pharmacotherapy, 2009, 10, 2209-2220.	0.9	33
65	Misdiagnosis of vertebral fractures on local radiographic readings of the multicentre POINT (Prevalence of Osteoporosis in INTERNAL medicine) study. Bone, 2017, 101, 230-235.	1.4	32
66	Genetic markers of osteoarticular disorders: facts and hopes. Arthritis Research, 2001, 3, 270.	2.0	31
67	Left Ventricular Diastolic Function Improvement by Carvedilol Therapy in Advanced Heart Failure. Journal of Cardiovascular Pharmacology, 2005, 45, 563-568.	0.8	31
68	Lasofoxitene: A new type of selective estrogen receptor modulator for the treatment of osteoporosis. Drugs of Today, 2006, 42, 355.	0.7	31
69	Feasibility of quantitative ultrasound measurements on the humerus of newborn infants for the assessment of the skeletal status. Osteoporosis International, 2004, 15, 541-6.	1.3	30
70	Relation of Plasma Brain Natriuretic Peptide Levels in Non-ST-Elevation Coronary Disease and Preserved Systolic Function to Number of Narrowed Coronary Arteries. American Journal of Cardiology, 2005, 96, 1705-1710.	0.7	29
71	The Potential Role of miRNAs as New Biomarkers for Osteoporosis. International Journal of Endocrinology, 2018, 2018, 1-10.	0.6	29
72	Treatment of post-menopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study. Clinical Endocrinology, 1997, 46, 55-61.	1.2	28

#	ARTICLE	IF	CITATIONS
73	Mild brachydactyly type A1 maps to chromosome 2q35-q36 and is caused by a novel IHH mutation in a three generation family. <i>Journal of Medical Genetics</i> , 2003, 40, 132-135.	1.5	28
74	Bazedoxifene for the prevention of postmenopausal osteoporosis. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 1229-1242.	0.9	28
75	Ospemifene use in postmenopausal women. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 839-849.	1.9	28
76	Comparison of intravenous and intramuscular neridronate regimens for the treatment of paget disease of bone. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 512-518.	3.1	28
77	Paget disease of bone-associated UBA domain mutations of SQSTM1 exert distinct effects on protein structure and function. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 992-1000.	1.8	28
78	Steroid hormone receptor gene polymorphisms and osteoporosis: a pharmacogenomic review. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 537-553.	0.9	27
79	Management of Osteoporosis in Men: A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13640.	1.8	26
80	Treatment options for glucocorticoid-induced osteoporosis. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 721-732.	0.9	25
81	Dual X-Ray and Laser Absorptiometry of the Calcaneus. <i>Journal of Clinical Densitometry</i> , 2004, 7, 349-354.	0.5	24
82	Aromatase Activity and Bone Loss in Men. <i>Journal of Osteoporosis</i> , 2011, 2011, 1-11.	0.1	24
83	Updates in epidemiology, pathophysiology and management strategies of glucocorticoid-induced osteoporosis. <i>Expert Review of Endocrinology and Metabolism</i> , 2020, 15, 283-298.	1.2	24
84	Telomerase Repeat Amplification Protocol (TRAP): A New Molecular Marker for Parathyroid Carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 1999, 265, 252-255.	1.0	23
85	The Effects of Zoledronic Acid on Serum Lipids in Multiple Myeloma Patients. <i>Calcified Tissue International</i> , 2008, 82, 258-262.	1.5	23
86	New and developing pharmacotherapy for osteoporosis in men. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 253-264.	0.9	23
87	Idiopathic Osteoporosis in Men. <i>Current Osteoporosis Reports</i> , 2013, 11, 286-298.	1.5	21
88	Identification of a novel locus on chromosome 2q13, which predisposes to clinical vertebral fractures independently of bone density. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 378-385.	0.5	21
89	Cardiovascular complications of mild autonomous cortisol secretion. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2021, 35, 101494.	2.2	21
90	The Use of Intravenous Aminobisphosphonates for the Treatment of Pagets Disease of Bone. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 1052-1063.	1.1	20

#	ARTICLE	IF	CITATIONS
91	Appropriate models for novel osteoporosis drug discovery and future perspectives. Expert Opinion on Drug Discovery, 2015, 10, 1201-1216.	2.5	20
92	Update on the pharmacogenetics of the vitamin D receptor and osteoporosis. Pharmacogenomics, 2009, 10, 417-433.	0.6	19
93	Giant cell tumor occurring in familial Paget's disease of bone: Report of clinical characteristics and linkage analysis of a large pedigree. Journal of Bone and Mineral Research, 2013, 28, 341-350.	3.1	19
94	Undiagnosed Vertebral Fractures Influence Quality of Life in Postmenopausal Women With Reduced Ultrasound Parameters. Clinical Orthopaedics and Related Research, 2014, 472, 2254-2261.	0.7	19
95	Mutation of <i>PFN1</i> Gene in an Early Onset, Polyostotic Paget-like Disease. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2553-2565.	1.8	19
96	Usefulness of Bone Quantitative Ultrasound in Management of Osteoporosis in Men. Journal of Clinical Densitometry, 2001, 4, 231-237.	0.5	18
97	Vitamin D Receptor Gene Polymorphisms Predict Acquired Resistance to Clodronate Treatment in Patients with Paget's Disease of Bone. Calcified Tissue International, 2008, 83, 414-424.	1.5	18
98	Glucocorticoid-induced osteoporosis: hope on the HORIZON. Lancet, The, 2009, 373, 1225-1226.	6.3	18
99	The impact of infarct size on regional and global left ventricular systolic function: a cardiac magnetic resonance imaging study. International Journal of Cardiovascular Imaging, 2015, 31, 1037-1044.	0.7	18
100	Cortisol Secretion, Sensitivity, and Activity Are Associated With Hypertension in Postmenopausal Eucortisolemic Women. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4441-4448.	1.8	18
101	Energy Metabolism and Ketogenic Diets: What about the Skeletal Health? A Narrative Review and a Prospective Vision for Planning Clinical Trials on this Issue. International Journal of Molecular Sciences, 2021, 22, 435.	1.8	18
102	Bona Fide Genetic Associations with Bone Mineral Density. New England Journal of Medicine, 2008, 358, 2403-2405.	13.9	17
103	Efficacy and safety of abaloparatide for the treatment of post-menopausal osteoporosis. Expert Opinion on Pharmacotherapy, 2019, 20, 805-811.	0.9	16
104	Emerging therapeutic targets for osteoporosis. Expert Opinion on Therapeutic Targets, 2020, 24, 115-130.	1.5	16
105	Aromatase activity and bone loss. Advances in Clinical Chemistry, 2011, 54, 129-164.	1.8	15
106	Helicobacter pylori seroprevalence in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2014, 43, 635-638.	3.1	15
107	Zoledronate in the prevention of Paget's (ZiPP): protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone. BMJ Open, 2019, 9, e030689.	0.8	15
108	Management and Medical Therapy of Mild Hypercortisolism. International Journal of Molecular Sciences, 2021, 22, 11521.	1.8	15

#	ARTICLE	IF	CITATIONS
109	Infection by CagA-positive <i>Helicobacter pylori</i> strains in patients with ischemic heart disease: prevalence and association with exercise-induced electrocardiographic abnormalities. <i>Digestive Diseases and Sciences</i> , 2002, 47, 831-836.	1.1	14
110	The Association of Body Composition and Sex Hormones with Quantitative Ultrasound Parameters at the Calcaneus and Phalanxes in Elderly Women. <i>Calcified Tissue International</i> , 2011, 89, 456-463.	1.5	13
111	Activation of the Wnt Pathway by Small Peptides: Rational Design, Synthesis and Biological Evaluation. <i>ChemMedChem</i> , 2017, 12, 2074-2085.	1.6	13
112	Preventive Role of Vitamin D Supplementation for Acute Phase Reaction after Bisphosphonate Infusion in Paget's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e466-e476.	1.8	13
113	Osteoporosis and Fragility Fractures in Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2020, 2020, 1-2.	1.0	13
114	Prediction of hypertension, diabetes and fractures in eucortisolemic women by measuring parameters of cortisol milieu. <i>Endocrine</i> , 2020, 68, 411-419.	1.1	13
115	Selenium: A Trace Element for a Healthy Skeleton - A Narrative Review. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021, 21, 577-585.	0.6	13
116	Perspectives in the treatment and prevention of osteoporosis. <i>Drugs of Today</i> , 2009, 45, 629.	0.7	13
117	Paget's disease of bone: an update on epidemiology, pathogenesis and pharmacotherapy. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 485-496.	0.5	12
118	Characteristics of Early Paget's Disease in <i>SQSTM1</i> Mutation Carriers: Baseline Analysis of the <i>ZIPP</i> Study Cohort. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 1246-1252.	3.1	12
119	Hidden hypercortisolism: a too frequently neglected clinical condition. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 1581-1596.	1.8	12
120	Current options for the treatment of Paget's disease of the bone. <i>Open Access Rheumatology: Research and Reviews</i> , 2009, 1, 107.	0.8	11
121	Lasofexifene: Selective Estrogen Receptor Modulator for the Prevention and Treatment of Postmenopausal Osteoporosis. <i>Annals of Pharmacotherapy</i> , 2011, 45, 499-509.	0.9	11
122	Infection by CagA-Positive <i>Helicobacter pylori</i> Strains and Bone Fragility: A Prospective Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 80-89.	3.1	11
123	Ospemifene Hormos. <i>Current Opinion in Investigational Drugs</i> , 2004, 5, 448-55.	2.3	11
124	Lasofexifene (Pfizer). <i>Current Opinion in Investigational Drugs</i> , 2005, 6, 1067-78.	2.3	11
125	Absence of Correlation Between BMP-4 Polymorphism and Postmenopausal Osteoporosis in Italian Women. <i>Calcified Tissue International</i> , 2000, 67, 93-94.	1.5	10
126	Epidemiological, clinical, and genetic characteristics of Paget's disease of bone in a rural area of Calabria, Southern Italy. <i>Journal of Endocrinological Investigation</i> , 2010, 33, 519-525.	1.8	10



#	ARTICLE	IF	CITATIONS
127	Vitamin D Status in Paget Disease of Bone and Efficacy of Safety Profile of Cholecalciferol Treatment in Pagetic Patients with Hypovitaminosis D. <i>Calcified Tissue International</i> , 2019, 105, 412-422.	1.5	10
128	Clinical, Laboratory and Lung Ultrasound Assessment of Congestion in Patients with Acute Heart Failure. <i>Journal of Clinical Medicine</i> , 2022, 11, 1642.	1.0	10
129	Optimization of a Monobromobimane (MBB) Derivatization and RP-HPLC-FLD Detection Method for Sulfur Species Measurement in Human Serum after Sulfur Inhalation Treatment. <i>Antioxidants</i> , 2022, 11, 939.	2.2	10
130	Osteoporosis in men: Pathophysiology and treatment. <i>Current Rheumatology Reports</i> , 2007, 9, 71-77.	2.1	9
131	Lasofexifene: Evidence of its therapeutic value in osteoporosis. <i>Core Evidence</i> , 2009, 4, 113.	4.7	9
132	Pathophysiology of Mild Hypercortisolism: From the Bench to the Bedside. <i>International Journal of Molecular Sciences</i> , 2022, 23, 673.	1.8	9
133	Pulmonary Congestion Assessment in Heart Failure: Traditional and New Tools. <i>Diagnostics</i> , 2021, 11, 1306.	1.3	8
134	When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis. <i>Endocrine Practice</i> , 2021, 27, 1216-1224.	1.1	8
135	Pharmacokinetic evaluation of toremifene and its clinical implications for the treatment of osteoporosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 505-513.	1.5	7
136	Management of bone fragility in type 2 diabetes: Perspective from an interdisciplinary expert panel. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2210-2233.	1.1	7
137	Bone Fragility in Gastrointestinal Disorders. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2713.	1.8	7
138	Estrogen in men: effects on bone accrual, maintenance and prevention of bone loss. <i>Expert Review of Endocrinology and Metabolism</i> , 2006, 1, 281-295.	1.2	6
139	Estrogen Effects on Bone in the Male Skeleton. , 2008, , 1801-1818.		6
140	Pharmacogenomics of Osteoporosis. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2010, 8, 77-94.	1.3	6
141	Osteoporosis in Men: Pathophysiology and treatment. <i>Current Osteoporosis Reports</i> , 2007, 5, 22-28.	1.5	5
142	Lasofexifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 205-217.	2.5	5
143	Interleukin-6 trans-signaling and pathological low back pain in patients with Paget disease of bone. <i>Pain</i> , 2018, 159, 1664-1673.	2.0	5
144	Falls, fractures and vitamin D: a never-ending story?. <i>Nature Reviews Rheumatology</i> , 2019, 15, 6-8.	3.5	5

#	ARTICLE	IF	CITATIONS
145	Effects of Bisphosphonate Treatment on Circulating Lipid and Glucose Levels in Patients with Metabolic Bone Disorders. <i>Calcified Tissue International</i> , 2021, 108, 757-763.	1.5	5
146	Letter to the Editor: The Endocrine Society Clinical Practice Guidelines on Paget's Disease: Many Recommendations Are Not Evidence Based. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, L45-L46.	1.8	5
147	Hypovitaminosis D and Organ Damage In Patients With Arterial Hypertension: A Multicenter Double Blind Randomised Controlled Trial of Cholecalciferol Supplementation (HYPODD). <i>High Blood Pressure and Cardiovascular Prevention</i> , 2015, 22, 135-142.	1.0	4
148	Increased Prevalence of Nephrolithiasis and Hyperoxaluria in Paget Disease of Bone. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4430-e4438.	1.8	4
149	Paget's disease of bone: epidemiology, pathogenesis and pharmacotherapy. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 591-603.	0.5	3
150	Grand Challenge in Adrenal Endocrinology: Is the Legacy of the Past a Challenge for the Future of Precision Medicine?. <i>Frontiers in Endocrinology</i> , 2021, 12, 747006.	1.5	3
151	PTH in the Pathogenesis and Treatment of Glucocorticoid-Induced Osteoporosis. , 2002, 30, 184-197.		2
152	Micro-RNA expression profiling in Paget's disease of bone. <i>Bone Abstracts</i> , 0, , .	0.0	2
153	Case Report: An Unusual Case of Acute Lower Limb Ischemia as Precursor of the Asherson's Syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 727276.	1.1	2
154	Left ventricular hypertrophy differences in male professional runners and in young patients suffering from mild hypertension. <i>Blood Pressure</i> , 2004, 13, 14-19.	0.7	1
155	Does calcium supplementation reduce the risk of osteoporotic fracture and bone loss?. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 70-71.	3.2	1
156	The Genetics of Peak Bone Mass. , 2010, , 149-163.		1
157	Recent advances in models for screening potential osteoporosis drugs. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 741-752.	2.5	1
158	Response to Letter to the Editor: "Methodological Issues Regarding Cortisol Secretion, Sensitivity, and Activity are Associated With Hypertension in Postmenopausal Eucortisolemic Women". <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 376-377.	1.8	1
159	Perspectives in the treatment and prevention of osteoporosis. <i>Drugs of Today</i> , 2009, 45, 629-47.	0.7	1
160	151 The Usefulness of Quantitative Ultrasound (QUS) Measurements in the Evaluation of Skeletal Status in Newborns and in Children. <i>Pediatric Research</i> , 2005, 58, 380-380.	1.1	0
161	Osteoporosis in men: Pathophysiology and treatment. <i>Current Sexual Health Reports</i> , 2008, 5, 83-89.	0.4	0
162	Lasofexifene: a new-generation SERM for the treatment of postmenopausal osteoporosis. <i>Expert Review of Obstetrics and Gynecology</i> , 2009, 4, 607-617.	0.4	0

#	ARTICLE	IF	CITATIONS
163	Nuove acquisizioni patogenetiche e terapeutiche ella malattia ossea di Paget. L Endocrinologo, 2013, 14, 120-127.	0.0	0
164	Zoledronic Acid Early Increases Serum Osteoprotegerin in Early Stage Multiple Myeloma.. Blood, 2006, 108, 3588-3588.	0.6	0
165	Malattia di Paget. , 2009, , 243-254.		0
166	Rachitismo e osteomalacia. , 2009, , 199-214.		0
167	Pharmacogenomics of bisphosphonate treatment in Paget's disease of bone: retrospective and prospective analysis. Bone Abstracts, 0, , .	0.0	0
168	Oral ibandronic acid. IDrugs: the Investigational Drugs Journal, 2005, 8, 155-69.	0.7	0